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Abstract
Introduction: Double contrast-enhanced ultrasonography (DCUS) is a new
method we used in predicting lymph node metastasis (LNM) in patients with
early gastric cancer.
Material and methods: Seventy-six patients with early gastric cancer diagnosed
by gastroscope and confirmed by pathology after operation were examined
using DCUS preoperatively. Group N1 included 15 patients with LNM and group
N0 61 patients without LNM.
Results: In group N1, 13 patients (87%) had marked hyperenhancement during
early arterial phase using DCUS, and 2 patients (13%) were unmarked as
hyperenhancement. In group N0, 24 patients (39%) had marked
hyperenhancement during early arterial phase using DCUS, and 37 patients
(61%) had unmarked hyperenhancement. The sensitivity and specificity of
marked hyperenhancement in predicting LNM in patients with early gastric
cancer was 86.7% and 60.7% respectively, and the Youden’s index was 0.474.
The κ value of this method was 0.89. 
Conclusions: Double contrast-enhanced ultrasonography is a new valuable
method to evaluate LNM at an early stage of gastric cancer and prognosis of
early gastric cancer preoperatively. 
Key words: early gastric cancer, lymph node metastasis, contrast-enhanced
ultrasonography.
Introduction
As a result of increased diagnostic accuracy and the wider application
of mass surveys, the proportion of early gastric cancer (EGC) among
resected gastric cancers has steadily increased, not only in Asia, but also
in some Western countries [1-6]. Although the prognosis of EGC is excellent
[7-9], EGC with lymph node metastasis (LNM) has a higher possibility of
recurrence [10-12]. Because the presence of LNM is the most important
prognostic factor for patients with EGC [3, 13-15], radical surgery with
extended (D2) lymph node dissection (LND) has become the gold standard
treatment for patients with EGC [16-19]. 
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Copyright © 2011 Termedia & BanachThe prevalence of LNM in EGC ranges from 10%
to 20% [20-24]. Therefore, at least 80% of patients
will undergo unnecessary surgery with D2
lymphadenectomy [8, 25, 26]. Bonenkamp et al.
[27] reported that patients with D2 lymph node
resection have a higher operative mortality rate
with more complications and a longer post  -
operative hospital stay. Recently, various minimally
invasive procedures such as endoscopic mucosal
resection and laparoscopic wedge resection
without LND have been performed in selected EGC
patients to improve the quality of life of long-term
survivors [28-35]. For such procedures, the accurate
prediction of LNM is crucial to determining the
extent of LND. 
Although it is extremely useful to know the
involvement of lymph nodes before surgery, there
is no simple and high sensitivity test to evaluate
lymph node status preoperatively. Diagnostic
imaging techniques including endoscopic
ultrasound (EUS), computed tomography (CT),
positron emission tomography (PET) and
ultrasonography (US) are still unsatisfactory and do
not provide enough evidence for an accurate
prediction of metastasis in the regional lymph
nodes draining gastric cancer because of their low
sensitivity [36-41]. It is also difficult to diagnose
such nodes during operation [42]. Because direct
detection of LNM with high sensitivity is impossible
yet, the indirect assessment of LNM in EGC is still
based on the pathobiologic behaviors of the tumor
[19, 43]. Accurate assessment of the pathobiologic
behaviors of the tumor needs resected specimens.
Biopsies are too superficial to provide the entire
information of the tumor [13]. 
Conventional trans-abdominal US has been
considered unsuitable for the detection of early
staging lesions and LNM [44]. Oral contrast agent
assisted US has been widely used to detect gastric
cancer in China. In the present study, we sought to
assess LNM of EGC preoperatively using double
contrast-enhanced ultrasonography (DCUS), an oral
ultrasonic contrast agent combined with an
intravenous contrast agent.
Material and methods
Eighty patients with EGC proven by pathology
were examined with DCUS preoperatively between
2005 and 2009 after obtaining written informed
consent. Of the 79 patients, 3 were excluded, one
with advanced gastric cancer and the other 2 with
the number of retrieved lymph nodes less than 15.
The remaining 76 patients were enrolled in this
study. The mean age of the patients was 58.3 years
(range 35-83). The male to female ratio was 1.71
(48/28). Written informed consent was obtained
from all patients. The ethics committee for our
institution approved the study.
In this study, all patients underwent curative
gastrectomy with D2 or more extended (D3)
lymphadenectomy for primary early GC. Surgical
resections were performed within 3 to 5 days after
the DCUS examination. None of the patients in this
study received nonsteroidal anti-inflammatory
drugs, chemotherapy, radiotherapy, or immuno  -
therapy before surgery. All of the subjects were
divided into 2 groups according to their lymph
nodes status postoperatively. Group N1 included 15
patients with LNM. Group N0 included 61 patients
without LNM.
Double contrast-enhanced ultrasonography was
performed after fasting for at least 6 h; Atropine
sulfate injection (0.05 mg/kg) was administered 
via intramuscular injection half an hour before the
examination to inhibit gastric peristalsis. An Acuson
Sequoia 512 system (Siemens, Mountain View, 
CA), equipped with a 4V1 vector™ transducer
(frequency: 1.0~4.0 MHz) and contrast pulse
sequencing (CPS) technology with auto-tracking
contrast quantification (ACQ) software was used
(Phillips and Gardner 2004). 
The oral contrast agent Xinzhang® (Huqingyutang,
HangZhou, China) was supplied as a microdot
powder which was composed of a kind of soya
derivative (48 g per package); it was reconstituted
by adding 500 ml of boiling water and gently
agitating the water by hand to form a homo  -
geneous particulate suspension.
The distal esophagus of all patients was
observed dynamically while the patients ingested
the oral ultrasonic agent to expand the stomach
and evacuate the air in stomach. Hence, the
stomach lumen appeared as an iso-echoic
homogenous acoustic window. Then the other parts
of the stomach and the duodenal bulb were
examined in turns with the patient in different body
positions. When a suspected lesion was identified,
it was measured routinely. If the lesion was smaller
than 5 cm, it would be zoomed in for higher spatial
resolution. Then after this procedure, a dynamic
real-time contrast-enhanced sonography with CPS
mode was performed using the following settings:
insonating frequency 1.5 MHz and acoustic power,
–15 to –21 dB. A low mechanical index (0.20) was
selected to minimize microbubble disruption.
Images of the ideal scanning plane were displayed
in a real-time fashion by slightly changing the
scanning plane to portray the whole area of the
tumor.
Contrast-enhanced sonographic studies were
performed after the administration of 2.4 ml of
SonoVue (Bracco SpA, Milan, Italy) as a bolus via
a 19-gauge peripheral intravenous cannula. The
cannula was flushed with 10 ml saline. A timer on
the sonography unit was activated at the beginning
of injection, and the entire movie sequence (at least
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5 min) was stored on magnetic optical disks for
analysis. The contrast study could be repeated
a second time if necessary.
The cine loops of the 69 lesions were
retrospectively reviewed by 2 independent
radiologists who are experts in sonography and
microbubble contrast agents. Vascular enhan  -
cement of gastric carcinomas was visually classified
into 3 patterns: hyper- enhancement, iso-
enhancement, and hypo-enhancement. Hyper-
enhancement was defined as a signal intensity over
the whole tumor higher than the adjacent normal
gastric wall during the whole arterial phase. Iso-
enhancement was defined as a signal intensity over
the whole tumor similar to the adjacent normal
gastric wall during the whole arterial phase. Hypo-
enhancement was defined as a signal intensity over
the whole tumor lower than the adjacent normal
gastric wall during the whole arterial phase.
According to the pattern of enhancement, all cases
were classified into the marked hyperenhancement
group and the unmarked hyperenhancement group
(including hypoenhancement and isoenhancement).
The 2 reviewers were unaware of the definitive
diagnosis and other imaging information at the
time of the analysis. Double contrast-enhanced
ultrasonography diagnoses were then compared
with the final diagnosis based on the pathologic
results.
Lymph nodes were meticulously dissected from
the en bloc specimens, and the classification of the
dissected lymph nodes was determined by
surgeons who reviewed the excised specimens after
surgery based on the Japanese Classification of
Gastric Carcinoma. The primary tumor and retrieved
lymph nodes were fixed in 10% formaldehyde
solution, embedded in paraffin, incised into 4 mm
sections, and mounted on poly-lysine-coated slides.
These sections were stained by hematoxylin-and-
eosin method to confirm their histological diagnosis
and other microscopic characteristics. Experienced
pathologists were employed to ensure a high
quality of pathological diagnosis. The following
clinicopathologic variables were evaluated: sex, age,
location of tumor (lower third, middle third, upper
third, or entire stomach), tumor diameter,
histological type (differentiated: well differentiated,
moderately differentiated, or papillary; undif  -
ferentiated: poorly differentiated, signet-ring cell,
or mucinous), LNM, and depth of invasion (mucosa
or submucosa).
Sensitivity, specificity and Youden’s index were
calculated for both oral contrast-enhanced
ultrasonography and DCUS. Statistical evaluation
was performed using the χ2 test or Fisher’s exact
test to differentiate the rates among the different
groups. Student’s t-test was used to analyze
quantitative data. Kappa statistics was used to
show the level of correlation in agreement between
the 2 reviewers. Kappa values are categorized as
follows [45]. Values between –1 and 0 indicate "no
agreement"; between 0 and 0.20 indicate "poor
agreement"; between 0.21 and 0.40 indicate "slight
agreement"; between 0.41 and 0.60 indicate "fair
agreement"; between 0.61 and 0.80 indicate "good
agreement"; between 0.81 and 0.90 indicate "very
good agreement"; and between 0.91 and 1.0
indicate "excellent agreement". For all analyses, 
a p value of less than 0.05 was considered
statistically significant. All data were analyzed using
SPSS13.0 statistical software (Chicago, IL, United
States).
Results
A total of 76 patients who had undergone
gastrectomy with D2 or more extended (D3)
lymphadenectomy for EGC at the 2nd Affiliated
Hospital of Wenzhou Medical College were studied.
The number of retrieved lymph nodes in all patients
was more than 15, ranging from 15 to 63 (median,
29.9). Lymph node metastasis was detected in 
15 patients (19.7%), and the number of metastatic
lymph nodes ranged from 1 to 36 (median 6.9). 
In group N1, 13 patients (87%) had marked
hyperenhancement compared with the adjacent
normal gastric wall during the early arterial phase
by using DCUS (Figure 1 C), and the other 2 patients
(13%) had unmarked hyperenhancement. However,
in group N0, 24 patients (39%) had marked early
hyperenhancement compared to the adjacent
normal gastric wall during the arterial phase using
DCUS, and the other 37 patients had unmarked
hyperenhancement (Figure 2 C). The sensitivity and
specificity of marked hyperenhancement in
predicting LNM in patients with early gastric cancer
were 86.7% and 60.7%, respectively, and the
Youden’s index was 0.474 (Table I). The relationships
between pathological characteristics of patients
and the type of contrast enhancement are
summarized in Table II. 
Discussion
Since LNM remains one of the most important
predictors for survival, reduction in lympha  -
denectomy will probably result in a residue of
metastatic lymph nodes [19]. Unnecessarily
extended resection will induce a series of
complications, which also result in a poor quality
of life [10, 46, 47]. Thus, it is important to
standardize the optimal extent of LND by
investigating LNM of EGC preoperatively.
The low sensitivities of EUS, CT, US and PET 
are insufficient to allow decision making on the
extent of lymphadenectomy [37-40]. Endoscopic
ultrasound, MR and CT mainly depend on lymph460 Arch Med Sci 3, June / 2011
AB
C Figure  1.  A case of EGC with LNM confirmed
pathologically after operation. A: The early gastric
cancer and LNM can not be detected with
conventional transabdominal US. B: The early gastric
cancer (white arrow) can be clearly demonstrated in
the oral contrast-enhanced ultrasonography image,
but LNM can not be demonstrated. C: Com  pared
with the adjacent normal gastric wall (white arrow),
marked hyperenhancement of the EGC (T) in DCUS
image was shown during the early arterial phase
STO – stomach, T – tumor, GB – gallbladder, L – liver
AB
C Figure 2. A case of EGC without LNM confirmed
pathologically after operation. A: The early gastric
cancer and LNM could not be detected with
conventional transabdominal US. B: The early gastric
cancer (white arrow) and LNM (green arrow) can be
clearly demonstrated in the oral contrast-enhanced
ultrasonography image. C: Compared with the
adjacent normal gastric wall (white arrow),
unmarked hyperenhancement of the EGC (green
arrow) in DCUS image was shown during the early
arterialphase
STO – stomach, GB – gallbladder
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node size as criteria to define malignancy [48].
Lymph nodes of less than 5 mm in diameter cannot
be accurately detected by available imaging
techniques [49-51]. In one study, 55% of the
metastatic lymph nodes were 5 mm or less in
diameter [52]. The lack of correlation between
lymph node size and metastatic infiltration has
been reported in studies of other solid tumors [53-
57]. Therefore, differentiating between benign and
metastatic lymph nodes may be unreliable when
lymph node size is used as a criterion [52]. Lymph
node metastasis of EGC is still predicted by means
of the presence or absence of certain tumor
characteristics postoperatively [19, 43, 58].
It is very difficult for conventional trans  -
abdominal US to visualize the gastric cancer
without any assistant because of the interference
of gas in the stomach (Figures 1 A, 2 A). Although
the likelihood of detecting gastric cancer followed
by oral contrast agent exist (Figures 1 B, 2 B), the
sensitivity of diagnosis of LNM of EGC by oral
contrast-enhanced ultrasonography is still very low
(Figure 1 B), with a rate of 33.3% in our study. 
Double contrast-enhanced ultrasonography
could be considered as a valid method to evaluate
the microcirculatory perfusion of gastric cancer
using intravenous contrast agents, based on taking
an oral ultrasonic agent. An oral ultrasonic agent
which was composed by a kind of soya derivative
has some contribution for this study, such as the
how to evacuate the air in stomach and distend the
gastric lumen for displaying the lesions prominently.
After taking the oral contrast agent, the stomach
lumen appeared as an iso-echoic homogenous
acoustic window, and its effect was superior to
water because the evacuation was slow. SonoVue,
a microbubble contrast material with a mean
diameter of 2.5 μm, is a blood pool agent that does
not cross into the interstitial space [59, 60]. 
Because such microbubbles flow with red blood
cells, the injected microbubbles act as markers for
tissues that are densely populated with vessels,
thereby, suggesting that angiogenesis is the
foundation for tumor enhancement [61, 62].
Angiogenesis is important for tumor growth and
metastasis [63-65]. Angiogenesis is an unfavorable
factor related to LNM in EG [66]. Double contrast-
enhanced ultrasonography can be used to assess
vascularity and the biological behavior of gastric
carcinomas in vivo [67]. 
Because of this finding, we sought to predict the
LNM in EGC preoperatively using DCUS by means
of certain primary tumor characteristics. Although
the specificity decreased from 98.4% with oral
contrast-enhanced ultrasonography to 60.7% with
DCUS (p < 0.005), the sensitivity was improved
from 33.3% with oral contrast-enhanced ultra  -
sonography to 86.7% with DCUS (p < 0.005).
Because the presence of LNM has a strong adverse
influence on the prognosis of patients with EGC [11,
Sensitivity  Specificity  Youden’s 
[%] [%] index
Oral CEUS 33.3 98.4 0.317
DCUS 86.7 60.7 0.474
Table I. The sensitivity, specificity,  and Youden’s
index of oral contrast-enhanced ultrasonography
(CEUS) and double contrast-enhanced ultra  -
sonography (DCUS) in detecting lymph node
metastasis
Factors Node negative Node positive Value of p Marked  Unmarked  Value of p
hyperenhancement hyperenhancement
Age [years] 61.0 ±13.5 57.7 ±10.3 0.382 58.5 ±10.9 58.2 ±11.1 0.887
Male 9 39 0.777 21 27 0.260
Female 6 22 16 12
Upper 2 2 0.291 2 2 0.446
Middle 2 8 3 7
Lower 11 51 32 30
Tumor  31.4 ±9.6 30.8 ±12.0 0.866 35.4 ±13.1 26.8 ±7.80 0.001
diameter [mm]
Mucosa 4 32 0.073 14 22 0.105
Submucosa 11 29 23 17
Histological type:
Differentiated 5 39 0.032 16 28 0.012
Undifferentiated 10 22 21 11
Table II. The relationship between different clinicopathological characteristics and the rate of lymph node metastasis
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22, 68-70], the high sensitivity of diagnosis is more
important. The agreement of this diagnosis is very
good (κ value = 0.89).
Intratumor microvessel density (MVD) is
a reliable index of tumor angiogenesis [71]. Many
previous studies of gastric carcinoma have
demonstrated that angiogenesis is one of the
crucial factors for tumor development and
progression in gastric cancer [72, 73]. Angiogenesis
is closely correlated with biological behaviors,
degree of differentiation, and metastatic
lymphadenopathy in gastric cancer [74]. Contrast-
enhanced intensity has a strong positive linear
correlation with MVD in gastric carcinoma [67].
Therefore, contrast-enhanced intensity is
a promising index to evaluate the growth and
progression of gastric carcinoma. This study
demonstrates that depth of tumor size and degree
of differentiation both relate to contrast-enhanced
intensity (p < 0.05), which indicates that contrast-
enhanced intensity can be used to assess the
biological behavior of EGC in vivo. We found that
degree of differentiation was significantly
associated with LNM (p < 0.05), similar to that
indicated by other authors [18, 19, 75]. 
Although contrast enhanced ultrasonography
can assess whether LNM is present in the patients
with DCUS, the location and number of lymph
nodes cannot be determined. Further studies are
required to evaluate LNM with precise quantitative
analysis.
In conclusion, DCUS shows promise as a new
noninvasive, convenient, and repeatable method to
evaluate LNM in EGC and the prognosis of EGC
preoperatively. Identification of EGC with marked
hyperenhancement allows closer postoperative
follow-up and possibly the use of drugs targeted
for the growth of new vessels to prevent recurrence.
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